Ingevity (NYSE:NGVT – Get Free Report) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 4.800-5.20 for the period, compared to the consensus earnings per share estimate of 4.760. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.
Wall Street Analysts Forecast Growth
Several brokerages recently commented on NGVT. BMO Capital Markets upped their target price on Ingevity from $64.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ingevity in a research report on Thursday, January 22nd. Wells Fargo & Company boosted their target price on shares of Ingevity from $60.00 to $65.00 and gave the company an “equal weight” rating in a report on Wednesday, January 28th. Zacks Research raised Ingevity to a “hold” rating in a research report on Tuesday, December 16th. Finally, Wall Street Zen cut Ingevity from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Ingevity presently has an average rating of “Hold” and an average target price of $67.50.
Check Out Our Latest Stock Report on Ingevity
Ingevity Stock Down 0.9%
Ingevity (NYSE:NGVT – Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.16). The company had revenue of $255.10 million during the quarter, compared to the consensus estimate of $257.27 million. Ingevity had a negative net margin of 5.14% and a positive return on equity of 103.69%. The firm’s revenue was down 3.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.95 earnings per share. Ingevity has set its FY 2026 guidance at 4.800-5.20 EPS. As a group, sell-side analysts predict that Ingevity will post 4.45 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of NGVT. Global Retirement Partners LLC bought a new position in shares of Ingevity in the fourth quarter worth about $27,000. Meeder Asset Management Inc. acquired a new stake in Ingevity in the 4th quarter valued at approximately $33,000. Kestra Advisory Services LLC bought a new position in Ingevity in the 4th quarter worth approximately $47,000. Geneos Wealth Management Inc. lifted its holdings in shares of Ingevity by 85.8% during the second quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after buying an additional 387 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new position in shares of Ingevity during the second quarter worth approximately $46,000. Institutional investors own 91.59% of the company’s stock.
Ingevity Company Profile
Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.
The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.
Featured Articles
- Five stocks we like better than Ingevity
- Gold Ran First – but This Cycle May Belong to Silver
- REVEALED: Something Big Happening Behind White House Doors
- MAJOR BUY ALERT: Mar-a-Lago/Trump/Elon
- Gilder: Don’t Buy AI Stocks, Do This Instead
- Read this or regret it forever
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.
